Targeting PD-1/PD-L1 interactions for cancer immunotherapy

被引：306
作者：
Zitvogel, Laurence [1 ,2 ,3 ,4 ]
Kroemer, Guido [3 ,5 ,6 ,7 ,8 ]
机构：
[1] Inst Gustave Roussy, INSERM, U1015, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Ctr Clin Invest CBT507, Villejuif, France
[3] Inst Gustave Roussy, Villejuif, France
[4] Univ Paris 11, Villejuif, France
[5] INSERM, U848, Villejuif, France
[6] Ctr Rech Cordeliers, Paris, France
[7] Hop Europeen Georges Pompidou, Paris, France
[8] Univ Paris 05, Fac Med, Paris, France
来源：
ONCOIMMUNOLOGY | 2012年 / 1卷 / 08期
关键词：
CELL CARCINOMA PATIENTS; CLINICAL-SIGNIFICANCE; PD-1; PATHWAY; B7-H1; EXPRESSION; MOLECULE; IMMUNOSUPPRESSION; RECEPTORS; LIGAND-1; ANTIBODY;
D O I：
10.4161/onci.21335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1223 / 1225
页数：3
相关论文
共 33 条
[1]   The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice [J].
Ansari, MJI ;
Salama, AD ;
Chitnis, T ;
Smith, RN ;
Yagita, H ;
Akiba, H ;
Yamazaki, T ;
Azuma, M ;
Iwai, H ;
Khoury, SJ ;
Auchincloss, H ;
Sayegh, MH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01) :63-69
[2]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[3]   Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses [J].
Butte, Manish J. ;
Keir, Mary E. ;
Phamduy, Theresa B. ;
Sharpe, Arlene H. ;
Freeman, Gordon J. .
IMMUNITY, 2007, 27 (01) :111-122
[4]  
Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
[5]   PD-L1 regulates the development, maintenance, and function of induced regulatory T cells [J].
Francisco, Loise M. ;
Salinas, Victor H. ;
Brown, Keturah E. ;
Vanguri, Vijay K. ;
Freeman, Gordon J. ;
Kuchroo, Vijay K. ;
Sharpe, Arlene H. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (13) :3015-3029
[6]   The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors [J].
Ghebeh, Hazem ;
Mohammed, Shamayel ;
Al-Omair, Abeer ;
Qattan, Amal ;
Lehe, Cynthia ;
Al-Qudaihi, Ghofran ;
Elkum, Naser ;
Alshabanah, Mohamed ;
Bin Amer, Suad ;
Tulbah, Asma ;
Ajarim, Dahish ;
Al-Tweigeri, Taher ;
Dermime, Said .
NEOPLASIA, 2006, 8 (03) :190-198
[7]   PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells [J].
Good-Jacobson, Kim L. ;
Szumilas, Courtney G. ;
Chen, Lieping ;
Sharpe, Arlene H. ;
Tomayko, Mary M. ;
Shlomchik, Mark J. .
NATURE IMMUNOLOGY, 2010, 11 (06) :535-U107
[8]   Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer [J].
Hamanishi, Junzo ;
Mandai, Masaki ;
Iwasaki, Masashi ;
Okazaki, Taku ;
Tanaka, Yoshimasa ;
Yamaguchi, Ken ;
Higuchi, Toshihiro ;
Yagi, Haruhiko ;
Takakura, Kenji ;
Minato, Nagahiro ;
Honjo, Tasuku ;
Fujii, Shingo .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (09) :3360-3365
[9]   The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells [J].
Haxhinasto, Sokol ;
Mathis, Diane ;
Benoist, Christophe .
JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (03) :565-574
[10]   Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma [J].
Hino, Ryosuke ;
Kabashima, Kenji ;
Kato, Yu ;
Yagi, Hiroaki ;
Nakamura, Motonobu ;
Honjo, Tasuku ;
Okazaki, Taku ;
Tokura, Yoshiki .
CANCER, 2010, 116 (07) :1757-1766
1234